To sign up     Investment     Messages    HR


Your present location:Home >> News >> 新闻动态 >> Product >> Venus Medtech Venibri Valve Dry Tissue technology presented on TCT 2016

Venus Medtech Venibri Valve Dry Tissue technology presented on TCT 2016

Date:2016-11-18 18:52

Dr. Hasan Jilaihawi
On the TCT conference, 2016 November 1st, Dr. Hasan Jilaihawi from New York University Meidcal center presented 《Venus A-valve design and clinical data update》.
He emphasized that the Venus A-valve by Venus Medtech is a self-expand valve device. It has more reasonable design comparing to the similar devices in the U.S. and Europe. And it is easier to operate during surgery – more suitable for Chinese patients’ needs. He also presented the first clinical use of the “pre-loading” and “dry tissue” technology of Venibri transcatheter valve, and said that this has brought tremendous change and breakthrough for the valve technology. Venibri transcatheter valve has the most advance “dry tissue” technology in the world. The product has completed its loading within the transferring device during its production process, this allow the product to be ready to use much quicker than other products. Surgeons can easily manage and reduce the waiting time for the patient. This lower the risks such as potential infection and more. Without the use of glutaraldehyde during its production process, the product has more resistance against calcify and has a prolonged shelf-life.

Dr. Hasan Jilaihawi
Venibri valve is the first transcatheter valve product using the pre-loading “dry tissue” technology. The valve had a successful first clinical implant; it also marked the new chapter of global cardio valve technology. 
  Transcatheter aortic valve implantation (TAVI or TAVR), a minimum invasive, low-risk treatment, brings the hope back for elder aortic stenosis patients, especially ones who are not suggested with open-heart surgery. TAVI has offered elder aortic stenosis patients a new hope. Currently, most transcatheter valve product in the market was produced and storage using glutaraldehyde, and will need the equipments for valve parts transfer during surgery. Now the TAVI has widely spread among the world, this kind of disadvantage of the product has gradually been revealed; such as the potential risks may cause by the delay of surgery progress, and the calcification issues caused by the usage of glutaraldehyde.      
Therefore, to develop an easier, lower risk, anti calcification and longer shelf-life valve became a new challenge for the transcather valve research team.
The “Heart Valve Research Institute” which was co-organised by the second of Affiliated hospital of ZheJiang University School of Medicine and Venus Medtech, has setup a co-working system with some of the top local research centers; such as National Engineering Research Center for Biomaterials Sichuan University, Fuwai Hospital, Chinese Academy of Medical Sciences, Zhongshan Hospital Fudan University, West China Hospital, Sichuan University. The Venibri transcatheter valve was one of the results of the collaboration. 
The worldwide famous German cardio disease expert professor Horst Sievert said “pre-loading technology is the milestone after transcatheter valve technology in 2002, it has made the heart valve replacement much easier just like a placing a stent, this is going to benefit a wide range of surgeons and patients. 

TypeInfo: Product

Keywords for the information: